Catalog No.: 101241

Net Contents: 100mg AggRecetin (Ristocetin)

AGGRECETIN® 100mg Ristocetin A Sulfate

AggRecetin® (Ristocetin) Reagent: Peak Platelet Precision with Over 90% Ristocetin Purity for Trusted RIPA Testing

AggRecetin® (Ristocetin) Reagent is intended for use in performing routine Ristocetin-Induced Platelet Aggregation (RIPA) testing on Platelet-Rich Plasma (PRP) samples to assess platelet function.

Optimized for RIPA Testing: Delivers reliable platelet aggregation results at both low and high Ristocetin concentrations.
Low-Dose RIPA Sensitivity: Facilitates detection of hyper-responsiveness in type 2B vWD and PT-vWD patients.
High-Dose RIPA Confirmation: Verifies normal platelet-vWF interaction or rules out qualitative defects in vWF.
Supports Targeted Guidelines: Aligns with international guidelines for vWD classification and platelet function evaluation.
Enables GPIb-vWF Binding Assessment: Reveals abnormalities in platelet receptor binding activity central to vWD pathology.

AggRecetin® (Ristocetin) Reagent is manufactured for precision in Ristocetin-Induced Platelet Aggregation (RIPA) testing, a critical assay in the evaluation of von Willebrand Disease (vWD). With a concentration exceeding 90% pure Ristocetin, AggRecetin ensures consistent and reliable platelet aggregation responses, delivering the confidence laboratories need for both screening and confirmation stages. This high-purity formulation minimizes variability and supports accurate interpretation of platelet-von Willebrand factor (vWF) interactions.

Designed to perform across a range of concentrations, AggRecetin is ideal for both low-dose and high-dose RIPA testing protocols. Low-dose RIPA testing is particularly sensitive for detecting hyper-responsiveness in patients with type 2B vWD and platelet-type vWD (PT-vWD), enabling early and precise identification of these subtypes. High-dose RIPA serves as a valuable confirmatory step, distinguishing between normal platelet function and potential qualitative abnormalities in vWF. This dual utility enhances confidence and helps guide appropriate clinical management.

Explore Product Data Sheet

Discover Expected Results Chart

AggRecetin plays a vital role in the evaluation workup of patients with suspected vWD, particularly when used within a comprehensive testing guidelines. Its use aligns with internationally recognized guidelines, making it a trusted component in the stratification and classification of vWD subtypes. By supporting a structured evaluation pathway, AggRecetin helps laboratories streamline workflows while upholding the highest standards of clinical accuracy.

Beyond classification, AggRecetin enables precise functional assessment of the GPIb-vWF interaction, a critical step in platelet adhesion. Abnormalities in this interaction are central to the pathophysiology of vWD, especially in type 2B and PT-vWD, where enhanced binding leads to abnormal platelet clumping. With AggRecetin, laboratories gain a powerful tool to explore these mechanisms, strengthening their evaluation capabilities and ensuring the most informed patient care decisions.

Kindly explore the materials provided on this page, including the AggRecetin Reagent Product Data Sheet and Routine Agonist Expected Results Chart. Additionally, refer to the and the AggRecetin Instruction for Use (IFU) and the AggRecetin Safety Data Sheet (SDS), available in six languages. For our European and United Kingdom customers and distributors, carefully review the AggRecetin EU Declaration of Conformity and the AggRecetin UK Declaration of Conformity to ensure compliance and tailored understanding for these specific regions. This information is crucial for gaining a comprehensive understanding of the product details and specifications.

Bio/Data Corporation’s Aggregation Reagents: Accessible Safety Data Sheets for Secure Handling

Bio/Data Corporation provides comprehensive Safety Data Sheets (SDS) for each of its carefully formulated aggregation reagents. These essential documents ensure safe handling, storage, and spill management while offering clear instructions on potential hazards. Designed for easy viewing, saving, and printing, the SDS are readily accessible to support a safe work environment and responsible chemical management.

Access Safety Data Sheet

Product Description

AggRecetin® is Ristocetin A Sulfate, a glycopeptide of unknown chemical structure isolated from Nocardia lurida. AggRecetin contains more than 90% Ristocetin A. AggRecetin (Ristocetin) Reagent has been optimized for use with Light Transmission Aggregometers. It may also be used with other turbidometric or impedance analyzers, and flow cytometers.

Review Instructions For Use

Intended Purpose

AggRecetin (Ristocetin) Reagent is intended for use in performing routine Ristocetin-Induced Platelet Aggregation (RIPA) testing on Platelet-Rich Plasma (PRP) samples to assess platelet function.

Detection / Measurement

AggRecetin (Ristocetin) Reagent is used, in conjunction with other diluents and control samples, to measure changes of the light transmission in a Platelet Rich Plasma (PRP) test sample.

Product Function

AggRecetin (Ristocetin) Reagent provides insight into different aspects of platelet function / quality. This Reagent aids in accessing various acquired and inherited platelet disorders or the efficacy of anti-platelet therapies

Test Principle

When introduced to a stirred, 37°C Platelet Rich Plasma (PRP) test sample, exogenous Reagents such as AggRecetin (Ristocetin) stimulate platelets, prompting them to undergo shape change and aggregate. This initial aggregation is called primary aggregation and is reversible. However, normal platelets possess the ability to release endogenous ADP from their granules, leading to a secondary, irreversible wave of aggregation. The Light Transmission Platelet Aggregometer effectively captures these changes by displaying parameters such as lag phase, shape change, and the rate and extent of aggregation over a predetermined testing period.

READ MORE... Easily Download the AggRecetin Reagent Instructions for Use in Your Selected Language.

Reagents Provided

AggRecetin (Ristocetin) Reagent, 100 mg.

Reagents and Materials Required but Not Provided

Purified Water (Distilled, Deionized, Reagent Grade), pH 5.3 – 7.2 for reconstitution
TRIS Buffered Saline (TBS) or 0.85% physiologic saline for dilutions

NOTE: USING BLOOD BANK SALINE WILL CAUSE ERRONEOUS RESULTS.

Materials and Accessories

Platelet Aggregometer
Centrifuge
Electronic Pipette
Pipette Tips
Aggregometer Test Tubes (Siliconized)
Aggregometer Stir Bars (Plastic Coated)
Plastic Sample Tubes and Caps (For Dilutions)

Reagent Storage

AggRecetin (Ristocetin) Reagent does not require temperature protection during shipment.
Upon receipt, store AggRecetin (Ristocetin) Reagent at 2 – 8° C in its original packaging.
Reconstituted AggRecetin (Ristocetin) Reagent is stable for 7 days when stored in its’ tightly capped, original container at 2 – 8° C.

AggRecetin Ristocetin Aggregation Reagent

AGGRECETIN IS AVAILABLE

IN TWO SIZES

Specific Information Provided

AggRecetin (Ristocetin) Reagent is not intended for the detection of a specific disorder, condition, or risk factor. AggRecetin (Ristocetin) Reagent is a distinctive platelet reagent employed in the realm of Ristocetin Induced Platelet Aggregation (RIPA) testing. Ristocetin interacts with von Willebrand Factor (vWF), a critical plasma protein involved in platelet adhesion and aggregation processes. Ristocetin prompts a conformational shift in vWF, exposing binding sites for platelet glycoprotein Ib (GP Ib). Consequently, platelet GP Ib receptors engage with vWF, initiating platelet adhesion. This initial adherence primes platelets for aggregation. In instances lacking von Willebrand Factor (vWF) or related platelet function disorders, Ristocetin Induced Platelet Aggregation proceeds to a limited extent due to platelets’ incapacity to aggregate effectively. Consequently, RIPA testing furnishes invaluable insights into platelet function / quality and vWF activity, thereby aiding in the characterization of von Willebrand Disease (vWD) and associated bleeding disorders. This testing method plays a vital role in evaluating platelet function / quality accurately.

Bio/Data Corporation's Commitment to IVDR Compliance
Bio/Data Corporation proudly complies with the stringent EU In Vitro Diagnostic Regulation (IVDR) 2017/746 and other relevant legislation. Through its Declaration of Conformity (DOC), the company ensures that its devices meet essential health, safety, and environmental standards.

Bio/Data Corporation's Commitment to UKCA Compliance
Bio/Data Corporation ensures product excellence by strictly adhering to UKCA regulations. The company's Declaration of Conformity (DOC) affirms its dedication to meeting health, safety, and environmental standards outlined in UKCA directives and any related updates, demonstrating its unwavering commitment to compliance.

View EU Declaration of Conformity

View UK Declaration of Conformity

AGGRECETIN® 100mg Ristocetin A Sulfate

AggRecetin® (Ristocetin) Reagent: Peak Platelet Precision with Over 90% Ristocetin Purity for Trusted RIPA Testing

AggRecetin® (Ristocetin) Reagent is intended for use in performing routine Ristocetin-Induced Platelet Aggregation (RIPA) testing on Platelet-Rich Plasma (PRP) samples to assess platelet function.

​​​​